Document Type
Article
Publication Title
Lancet Regional Health - Americas
Volume
11
DOI
10.1016/j.lana.2022.100263
First Page
1
Last Page
3
Publication Date
5-18-2022
Abstract
Structural racism is endemic in the United States and causes inequitable health outcomes that have been amplified throughout the COVID-19 pandemic. Non-Hispanic Black, Hispanic/Latino, and Native American individuals have been disproportionately affected, and are twice as likely to be hospitalized or die from COVID-19 or related morbidities when compared to White Americans. Social determinants of health inequities contribute to these disparate outcomes, given that minoritized individuals are more likely to occupy essential worker roles and to live in high-density settings. Despite their higher risk of severe COVID-19 illness, racially and ethnically minoritized individuals are less likely to receive potentially lifesaving COVID-19 therapeutics.3 While several state health departments attempted to implement race-conscious interventions and narrow the disparities, these efforts have been met with fallacious claims of ‘reverse racism’ and the reversal of the proposed implementations.
Recommended Citation
Abdul-Mutakabbir, J. C.,
Hirsch, E. B.,
Ko, C. L.,
Brown, B. R.,
Bandali, A.,
Mordino, J.,
Yoke, L. H.,
Bell, T.,
Swartz, T. H.,
Syed, U.,
Hlatshwayo, M.,
&
Saunders, I. M.
(2022).
A call to action: A need for initiatives that increase equitable access to COVID-19 therapeutics.
Lancet Regional Health - Americas, 11, 1–3.
DOI: 10.1016/j.lana.2022.100263
https://scholarlycommons.pacific.edu/phs-facarticles/632
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
